Aerie Pharmaceuticals

Aerie Pharmaceuticals Inc. (NASDAQ: AERI) is a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie's two lead product candidates are once-daily IOP-lowering therapies with novel mechanisms of action to treat patients with glaucoma or ocular hypertension.[1][2][3]

Aerie Pharmaceuticals
Publicly traded
Traded asNASDAQ: AERI
Russell 2000 Component
Industrypharmaceutical companies
Headquarters
United States of America 
Websiteaeriepharma.com

References
  1. Witkowski, Wallace (16 September 2015). "Aerie Pharma Shares Skyrocket On Glaucoma Drug Study Results". Fox Business.
  2. Beckerman, Josh. "Aerie Pharmaceuticals Shares Rise on Trial Results". Wall Street Journal.
  3. "Aerie Pharma shares battered as eye drug fails study". Reuters. 23 April 2015. Retrieved 7 January 2016.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.